drugset / Trial / NCT02541331

Efficacy Of Bacterial Lysate In Asthmatic Children

NCT02541331 ↗

Phase 3 Completed 150 enrolled Lallemand Pharma AG
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study evaluate the efficacy of Mechanical Bacterial Lysate (PMBL - Ismigen®) to improve the asthma control level (ACT score) as add-on treatment to routine asthma treatment in children aged 6 to 16 with uncontrolled or partly controlled asthma. Half of the 150 participants will receive Ismigen® and their current asthma therapy while the other half will receive Placebo and their current asthma treatment.

Timeline

Start
2014-07
Primary completion
2015-06
Completion
2015-06

Outcome

Missed primary endpoint

paper The main criterion was not achieved as ACT/C-ACT changes were similar in both groups at the end of the 3-month treatment period. PMID 29575037 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ismigen Vaccine — Other

Indications